Quantum Computing is trading at $6.39, down 5.09%, amid technology-sector weakness and investor concerns about financing costs for AI infrastructure.

  • On October 16, 2026, software stocks were also under pressure.
  • The INmune Bio collaboration, announced October 14, was presented as Quantum Computing’s first pharmaceutical and biotechnology customer; available coverage linked it to the earlier rally, not this decline.
  • Available reporting described trading volume as lighter than average.